Sensus Healthcare (NASDAQ:SRTS) Issues Earnings Results

Sensus Healthcare (NASDAQ:SRTS) announced its quarterly earnings data on Thursday. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.06, Zacks reports. Sensus Healthcare had a negative net margin of 2.26% and a negative return on equity of 1.58%.

Sensus Healthcare Price Performance

Shares of SRTS stock traded down $0.17 during trading hours on Thursday, hitting $3.52. The company had a trading volume of 294,978 shares, compared to its average volume of 168,475. The company’s fifty day moving average is $3.26 and its 200 day moving average is $4.09. Sensus Healthcare has a fifty-two week low of $3.03 and a fifty-two week high of $9.33. The stock has a market capitalization of $57.87 million, a PE ratio of -58.67 and a beta of 1.38.

Analyst Ratings Changes

Several brokerages recently issued reports on SRTS. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sensus Healthcare in a research note on Wednesday, October 8th. Lake Street Capital dropped their price objective on shares of Sensus Healthcare from $13.00 to $6.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Zacks Research raised shares of Sensus Healthcare from a “strong sell” rating to a “hold” rating in a research note on Wednesday, October 22nd. Finally, HC Wainwright dropped their price objective on shares of Sensus Healthcare from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, August 12th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.00.

Institutional Investors Weigh In On Sensus Healthcare

A hedge fund recently raised its stake in Sensus Healthcare stock. Geode Capital Management LLC increased its holdings in shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) by 2.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 153,917 shares of the company’s stock after buying an additional 3,766 shares during the period. Geode Capital Management LLC owned about 0.94% of Sensus Healthcare worth $730,000 at the end of the most recent quarter. Institutional investors own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.